JP2022524083A5 - - Google Patents

Info

Publication number
JP2022524083A5
JP2022524083A5 JP2021553012A JP2021553012A JP2022524083A5 JP 2022524083 A5 JP2022524083 A5 JP 2022524083A5 JP 2021553012 A JP2021553012 A JP 2021553012A JP 2021553012 A JP2021553012 A JP 2021553012A JP 2022524083 A5 JP2022524083 A5 JP 2022524083A5
Authority
JP
Japan
Prior art keywords
therapeutically active
active biological
individual
biological agents
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021553012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524083A (ja
JP7618239B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2019/028750 external-priority patent/WO2019209845A1/en
Application filed filed Critical
Priority claimed from PCT/US2020/021742 external-priority patent/WO2020185699A1/en
Publication of JP2022524083A publication Critical patent/JP2022524083A/ja
Publication of JP2022524083A5 publication Critical patent/JP2022524083A5/ja
Priority to JP2024195155A priority Critical patent/JP2025020335A/ja
Application granted granted Critical
Publication of JP7618239B2 publication Critical patent/JP7618239B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021553012A 2019-03-08 2020-03-09 薬物に依存しない患者固有の投薬レジメンのためのシステムおよび方法 Active JP7618239B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024195155A JP2025020335A (ja) 2019-03-08 2024-11-07 薬物に依存しない患者固有の投薬レジメンのためのシステムおよび方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962815825P 2019-03-08 2019-03-08
US62/815,825 2019-03-08
USPCT/US2019/028750 2019-04-23
PCT/US2019/028750 WO2019209845A1 (en) 2018-04-23 2019-04-23 Systems and methods for modifying adaptive dosing regimens
US16/391,950 US20190326002A1 (en) 2018-04-23 2019-04-23 Systems and methods for modifying adaptive dosing regimens
US16/391,950 2019-04-23
PCT/US2020/021742 WO2020185699A1 (en) 2019-03-08 2020-03-09 Systems and methods for drug-agnostic patient-specific dosing regimens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024195155A Division JP2025020335A (ja) 2019-03-08 2024-11-07 薬物に依存しない患者固有の投薬レジメンのためのシステムおよび方法

Publications (3)

Publication Number Publication Date
JP2022524083A JP2022524083A (ja) 2022-04-27
JP2022524083A5 true JP2022524083A5 (cg-RX-API-DMAC7.html) 2023-03-17
JP7618239B2 JP7618239B2 (ja) 2025-01-21

Family

ID=72426742

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021553012A Active JP7618239B2 (ja) 2019-03-08 2020-03-09 薬物に依存しない患者固有の投薬レジメンのためのシステムおよび方法
JP2024195155A Pending JP2025020335A (ja) 2019-03-08 2024-11-07 薬物に依存しない患者固有の投薬レジメンのためのシステムおよび方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024195155A Pending JP2025020335A (ja) 2019-03-08 2024-11-07 薬物に依存しない患者固有の投薬レジメンのためのシステムおよび方法

Country Status (8)

Country Link
EP (1) EP3935639A1 (cg-RX-API-DMAC7.html)
JP (2) JP7618239B2 (cg-RX-API-DMAC7.html)
KR (1) KR102839034B1 (cg-RX-API-DMAC7.html)
AU (2) AU2020239014A1 (cg-RX-API-DMAC7.html)
CA (1) CA3132823A1 (cg-RX-API-DMAC7.html)
IL (1) IL286145A (cg-RX-API-DMAC7.html)
SG (1) SG11202109704UA (cg-RX-API-DMAC7.html)
WO (1) WO2020185699A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12064664B2 (en) 2020-11-10 2024-08-20 Willowview Consulting, Llc Method and system for dynamically transforming user health and exercise-related data into visual, audio, textual, and physical data representations
US20220199266A1 (en) * 2020-12-10 2022-06-23 DataRobot, Inc. Systems and methods for using machine learning with epidemiological modeling
CN113643785B (zh) * 2021-07-22 2023-09-01 海南大学 基于dikw图谱的疫苗接种浓度确认方法
JP2023127482A (ja) * 2022-03-01 2023-09-13 株式会社島津製作所 試料分析装置、試料分析方法、医薬分析装置および医薬分析方法
CN114765076A (zh) * 2022-04-18 2022-07-19 柳州市妇幼保健院 新生儿个体化氟康唑给药量计算方法及给药方案推荐系统
KR102834065B1 (ko) * 2022-09-22 2025-07-16 서울대학교산학협력단 약동학적 변화량 예측 장치 및 방법
CN116453669B (zh) * 2023-06-14 2023-08-25 武汉大学中南医院 一种基于大数据的护理预测方法及装置
WO2025006459A1 (en) * 2023-06-29 2025-01-02 Prxcision, Inc. Machine learning for real-time decision support
CN118016237A (zh) * 2024-01-22 2024-05-10 南栖仙策(南京)高新技术有限公司 给药剂量确定方法、装置、电子设备及存储介质
CN120448609B (zh) * 2025-07-11 2025-09-16 上海斯丹姆医药开发有限责任公司 一种流感疫苗临床试验中的数据可视化方法及系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023211A1 (en) * 2000-09-15 2004-02-05 Kees Groen System and method for optimizing drug theraphy for the treatment of diseases
EP2171630A1 (en) * 2007-06-27 2010-04-07 F. Hoffmann-Roche AG System and method for developing patient specific therapies based on modeling of patient physiology
US20130191097A1 (en) * 2010-01-04 2013-07-25 Mayo Foundation For Medical Education And Research Erythropoietic stimulating agent (esa) dosage determination
US20130041683A1 (en) 2010-04-07 2013-02-14 Novacare Computer based system for predicting treatment outcomes
WO2014055978A1 (en) 2012-10-05 2014-04-10 Baysient LLC System and method for providing patient-specific dosing as a function of mathematical models
US11501863B2 (en) 2015-04-09 2022-11-15 Diane R. MOULD Systems and methods for patient-specific dosing
JP2018190244A (ja) * 2017-05-09 2018-11-29 塩野義製薬株式会社 生理学的モデルによる新規ヒト血漿中濃度推移の予測法

Similar Documents

Publication Publication Date Title
Andrade-Junior et al. Skeletal muscle wasting and function impairment in intensive care patients with severe COVID-19
Garibaldi et al. Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19
Najjar et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial
Laupacis et al. The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin
Berendes et al. Reversible cardiac sympathectomy by high thoracic epidural anesthesia improves regional left ventricular function in patients undergoing coronary artery bypass grafting: a randomized trial
Mulherin et al. Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ
Wu et al. Systematic review of motor function scales and patient-reported outcomes in spinal muscular atrophy
Renaud et al. Sparing of muscle mass and function by passive loading in an experimental intensive care unit model
JP4560081B2 (ja) 薬剤の計時投薬の改良された方法
CN111888463B (zh) 用于治疗抑郁症的胸腺素β4药物制剂与制备方法及其应用
Boyle et al. The role of inflammation in acute psychosocial stress-induced modulation of reward processing in healthy female adults
Magréault et al. Dosing and route of administration of clindamycin given in combination with rifampicin
US20080249020A1 (en) Human Growth Hormone Treatment Methods
Sun et al. Exercise improves pulmonary fibrosis and neurological symptoms via S100A12 inhibition
JP2024527230A5 (cg-RX-API-DMAC7.html)
Pereiras et al. Does oral vancomycin prophylaxis for Clostridium difficile infection improve allogeneic hematopoietic stem cell transplant outcomes?
WO2023102970A1 (zh) 甲状旁腺激素在制备治疗男性抑郁症的药物或保健品中的应用
RU2449278C1 (ru) Способ прогноза развития нейтропении, вызванной комбинированной противовирусной терапией, у больных хроническим гепатитом с
Kang et al. Up-regulation of peroxisome proliferator-activated receptor γ in perennial allergic rhinitis
Otimenyin Dosage regimen
Li et al. Safety, pharmacokinetics and population pharmacokinetic model of TQH2722, a novel IL-4Rα monoclonal antibody in healthy subjects: a phase I, first-in-human, single-dose and multiple-dose escalation study
Byrne et al. Cipaglucosidase alfa plus miglustat in Pompe disease: two non-ambulatory patients switching from high‑dose, high-frequency alglucosidase alfa
Linfield et al. Impact of Apitegromab on Motor Function in Spinal Muscular Atrophy
Francesco Evidence-based modalities in the management of Psoriasis and Psoriatic arthritis
Johannsen et al. O-247 The intrafollicular inflammatory response during ovulation in women is most likely controlled by high concentrations of active cortisol being synthesized shortly before follicular rupture